Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
The SELECT-SWITCH study, first head-to-head Phase 3b/4 trial, compared switching to Rinvoq versus switching to another TNF inhibitor
Lilly's Omvoh is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
FDA authorization was based on two years of clinical study data demonstrating that Essilor Stellest lenses significantly slowed myopia progression compared to single-vision control lenses
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
Subscribe To Our Newsletter & Stay Updated
